The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

Conditions

• Post Cataract Surgery

Eligibility Criteria

Sex

ALL

Age

22 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Triamcinolone (Optional) — DRUG
  triamcinolone 40mg/ml or topical clobetasol 0.05% with nepafenac 0.3% QD for 14 days
• control group — DRUG
  topical medication regimen will include prednisolone acetate 1% QID, ketorolac 0.5% QID, and moxifloxacin 0.5% topical drops QID.

Study Details

A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.

Key Dates

Start date

Apr 1, 2026

Status verified

Oct 2025

Primary completion

Dec 31, 2026

Completion

Jan 31, 2027

Study Design

Enrollment

40 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Arms

• Experimental: Experimental Group
  Triesence or Byqlovi Arm with nepafenac
• Active Comparator: Control Group
  Topical Moxifloxacin, Ketorolac, Prednisolone Acetate

Primary Outcome Measure

Primary [ Time Frame: 14 days after cataract surgery in each eye ]

Central Contacts

• John Hovanesian, MD
  949-951-2020
  [email protected]
• Leslie Lemieux, MHA
  [email protected]

Locations (1)

Find similar trials in Laguna Hills, CA